医学
内科学
肿瘤科
中止
化疗
癌症
卵巢癌
外科
作者
Malak Moubarak,Philipp Harter,Beyhan Ataseven,Alexander Traut,Julia Welz,Thaïs Baert,Florian Heitz
标识
DOI:10.1016/j.gore.2022.100939
摘要
We aimed to evaluate real-life experiences with the re-challenge of poly(ADP-Ribose)Polymerase (PARP) inhibitors (PARPi) after a prior PARPi therapy in patients with recurrent EOC.
科研通智能强力驱动
Strongly Powered by AbleSci AI